S

Sanquin

Europe, Noord-Holland, The Netherlands, Amsterdam

Description

Sanquin provides the blood supply in the community and contribute to people's quality of life with their targeted medication services.

Investor Profile

Sanquin has made 3 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Convertible Note (33%)
  • Series A (33%)
  • Seed (33%)

Country Focus

  • The Netherlands (100%)

Industry Focus

  • Biotechnology
  • Life Science
  • Therapeutics
  • Biopharma
  • Emergency Medicine
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Sanquin frequently co-invest with?

Thuja Capital
Europe, Utrecht, The Netherlands, Utrecht
Co-Investments: 1
OostNL
Europe, Gelderland, The Netherlands, Apeldoorn
Co-Investments: 3
Medicxi
Europe, England, United Kingdom, London
Co-Investments: 1
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Waterman Ventures
North America, New Hampshire, United States, Manchester
Co-Investments: 1
Veloxis
Europe, Hovedstaden, Denmark, Hørsholm
Co-Investments: 1
Broadview Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 1

What are some of recent deals done by Sanquin?

Alveron Pharma

Nijmegen, Gelderland, The Netherlands

Alveron produces drugs such as cyclodextrins, pro-coagualant cyclodextrins with a unique coagulation platform technology.

BiopharmaBiotechnologyEmergency MedicinePharmaceutical
SeedDec 6, 2024
Amount Raised: $5,287,810
Xenikos

Nijmegen, Gelderland, The Netherlands

Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.

BiotechnologyLife ScienceTherapeutics
Convertible NoteSep 8, 2021
Amount Raised: $47,275,792
Xenikos

Nijmegen, Gelderland, The Netherlands

Xenikos is developing a combination of two toxin-loaded anti-T-cell antibodies.

BiotechnologyLife ScienceTherapeutics
Series AJun 19, 2012
Amount Raised: $4,564,381